Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History IMTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics IMTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Immatics NV

IMTX
Current price
5.54 USD -0.13 USD (-2.21%)
Last closed 5.71 USD
ISIN NL0015285941
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 694 050 496 USD
Yield for 12 month -53.29 %
1Y
3Y
5Y
10Y
15Y
IMTX
21.11.2021 - 28.11.2021

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. Address: Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

14.33 USD

P/E Ratio

Dividend Yield

Financials IMTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures IMTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+183 362 259 USD

Last Year

+63 535 226 USD

Current Quarter

+21 864 392 USD

Last Quarter

+66 188 557 USD

Current Year

+183 362 259 USD

Last Year

-76 088 837 USD

Current Quarter

+21 864 392 USD

Last Quarter

+66 188 557 USD
EBITDA -51 664 000 USD
Operating Margin TTM -190.37 %
Price to Earnings
Return On Assets TTM -5.84 %
PEG Ratio
Return On Equity TTM -4.78 %
Wall Street Target Price 14.33 USD
Revenue TTM 144 148 000 USD
Book Value 4.42 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -38.60 %
Dividend Yield
Gross Profit TTM -13 731 000 USD
Earnings per share -0.20 USD
Diluted Eps TTM -0.20 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -15.54 %

Stock Valuation IMTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.35
Price Sales TTM 4.81
Enterprise Value EBITDA 7.19
Price Book MRQ 1.07

Technical Indicators IMTX

For 52 Weeks

3.30 USD 13.09 USD
50 Day MA 5.28 USD
Shares Short Prior Month 4 990 505
200 Day MA 6.59 USD
Short Ratio 5.76
Shares Short 4 385 373
Short Percent 4.44 %